New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTestagen vs ARA-290

Testagen vs ARA-290

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Testagen
Immune SupportRecovery & Repair
ARA-290
Summary
Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2–4 hours (SC administration)
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
4 mg (fixed dose)
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports endogenous testosterone synthesis via Leydig cell normalization
  • Promotes spermatogenesis and sperm quality
  • Anti-aging effects on testicular tissue
  • May attenuate age-related testosterone decline
  • Mechanistically distinct from TRT — does not suppress HPG axis
  • Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
  • Supports male fertility without exogenous hormone replacement
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant endocrine disruption reported at standard doses
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
Stacks With